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Influenza causes respiratory infections and poses health risks to humans and animals; its
effects are complicated by increasing resistance to existing anti-influenza viral agents.
Therefore, novel therapeutic approaches against influenza virus infection are required.
Psoraleae semen has been widely used in traditional medicine in Korea, Taiwan, China,
and Japan for treating and preventing various diseases. In this study, we examined the
anti-viral activities and mechanism of action of the water extract of Psoraleae semen
(WPS) using RAW 264.7 and MDCK cells. We found that pre- and post-treatment with
100 µg/mL WPS markedly inhibited influenza A virus replication as assessed using a
green fluorescent protein reporter virus, reduced viral protein expression (NS-1, PA, HA,
PB-1, M1, and M2), and inhibited NA and HA activities. Mechanism studies revealed that
WPS induced type I interferon cytokine secretion and subsequent stimulation of an anti-
viral state in RAW 264.7 cells. Further, WPS exerted inhibitory effects on neuraminidase
in influenza virus strains H1N1 and H3N2. Meanwhile, WPS exhibited inhibitory effects
on hemagglutination in H3N2 but not in H1N1. Based on these results, WPS serves as
an immunomodulator and inhibitor of influenza hemagglutinin and neuraminidase. Our
results suggest that WPS is a promising source of novel anti-influenza drug candidates.
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INTRODUCTION
Influenza viruses belong to the Orthomyxoviridae family. There are three types of influenza
viruses: A, B, and C (Zambon, 1999). Influenza virus A can infect humans and different animals,
including domestic and wild birds (Capua and Alexander, 2004). However, infection by type
B and C viruses is mainly restricted to humans (Capua and Alexander, 2004). Influenza A
virus (IAV) is the most serious influenza type as IAV infection can result in serious respiratory
illness, respiratory complications, major economic loss, and death; additionally, the virus is
particularly virulent among the elderly (Monto and Sullivan, 1993; Fleming et al., 2000; Fiore
et al., 2009). Vaccines represent the most effective strategy for controlling influenza virus infection,
but influenza vaccines have disadvantages, including inadequate protection, high cost, difficulty
in predicting representative strains, and time requirements for design and production (Hayden,
2006; Fiore et al., 2009). Therefore, alternative strategies are required for efficiently controlling
influenza outbreaks. There are two classes of anti-influenza drugs: neuraminidase (NA) inhibitors
(oseltamivir, zanamivir, and peramivir) and adamantanes (amantadine and rimantadine; Meijer
et al., 2014). However, high resistance levels have been reported for adamantanes against IAV, and
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these drugs are ineffective against influenza B virus (Centers for
Disease and Prevention, 2006; Ison, 2011). NA inhibitors are
widely used for treating and preventing influenza virus infection
(Meijer et al., 2014). Numerous reports have illustrated that
IAVs develop resistance to oseltamivir, zanamivir and peramivir
(Centers for Disease and Prevention, 2006; Bouvier et al., 2008;
Hurt et al., 2009). Further, NA inhibitors have several side effects
(Kaji et al., 2005). Thus, there is a critical need to develop
novel anti-influenza drugs to control and prevent future influenza
pandemics and epidemics.
The innate immune system that includes type I interferons
(IFNs) promotes innate anti-viral and anti-bacterial immunities
(Anderson, 2000). Type I IFNs, namely α and β, are regulated
by IFN regulatory factor (IRF)-7, IRF-3, NF-κB, and several
intracellular signaling molecules, which are activated by
germline-encoded pattern recognition receptors recognizing
the molecular pattern specific to microorganisms (Marié et al.,
1998; Sato et al., 2000). During viral infection, rapid IFN
production is needed to prevent the spread of the virus in the
host. Medicinal plants have been the most important sources of
medicine worldwide for some time, and they will be continue
to serve as sources of novel remedies for humans. Medicinal
plants exhibit numerous beneficial therapeutic properties, and
it is thought that the mechanisms involved in these effects are
due to the modulation of innate immunity. In particular, a lot
of extracts or substances from medicinal herbs or plants have
anti-viral effects against infectious viruses (Cowan, 1999; Cho
et al., 2015). Therefore, natural product or standardized plant
extracts provide unlimited opportunities for new anti-viral drugs
with high efficacies, low toxicities, and minor side effects.
Psoraleae semen (PS) has been widely used in traditional
Korean, Chinese, and Asian herbal medicine to treat various
diseases and conditions such as several skin diseases including
leukoderma, cardiovascular diseases, nephritis, osteoporosis,
cancer, and hair loss (Khushboo et al., 2010; Zhang et al., 2016).
Additionally, PS extracts and active components possess many
pharmacological and biological activities, including, estrogenic,
anti-microbial, anti-depressant, anti-inflammatory, anti-oxidant,
hypotensive, osteoblastic, hepatoprotective, and anti-tumor
activities (Zhang et al., 2016). The main PS components include
flavonoids, coumarins, and meroterpenes, and the major active
compounds are bakuchiol, bavachin, angelicin, psoralen, and
corylifolin (Zhang et al., 2016). Psoralen inactivates influenza
viruses, herpes simplex viruses, and vesicular stomatitis virion
RNA polymerase activity (Nakashima et al., 1979; Redfield et al.,
1981), and angelicin derivatives inhibit influenza virus (Yeh et al.,
2010). Recently, bakuchiol was shown to have anti-influenza viral
activity by Nrf2 activation (Shoji et al., 2015). Consequently, a
PS extract could be a candidate with anti-influenza virus activity.
We hypothesize that water extract of PS (WPS) induces an
anti-viral state in murine macrophage cells (RAW 264.7) via
the modulation of the immune response, induction of anti-viral
cytokines, and overall inhibition of virus replication.
Here we investigated WPS-induced signaling molecules and
confirmed the immunomodulatory potential of these molecules
to regulate the innate immune response of PS, which may
be responsible for its anti-viral activity in murine macrophage
cells. Further, we evaluated PS efficacy against IAVs in vitro.
Finally, prophylactic WPS efficacies against divergent influenza
A subtypes, including H1N1 and H3N2, were assessed.
MATERIALS AND METHODS
WPS Preparation
The PS identity obtained from Yeongcheon Oriental Herbal
Market (Yeongcheon, Korea) was first certificated by Professor
Ki Hwan Bae (College of Pharmacy, Chungnam National
University, Daejeon, Korea), and PS was stored in the KM-
Application Center herbarium, Korea Institute of Oriental
Medicine. To prepare WPS, dried PS (50 g) was soaked in
distilled water (1 L) and then heat-extracted at 115◦C for 3 h in
a Cosmos-600 Extractor (Gyeonseo Co., Incheon, Korea). After
filtration through standard testing sieves (150 µm, Retsch, Haan,
Germany), WPS was freeze-dried and stored in desiccators at
4◦C. The amount of WPS powder collected was 15.6 g, and the
yield was 12.96%.
Cells and Viruses
RAW 264.7 and MDCK cells were obtained from the American
Type Culture Collection (Manassas, VA, USA). Cells were
maintained in DMEM or RPMI 1640 (Lonza, Walkersville,
MD, USA) supplemented with 10% (v/v) heat-inactivated fetal
bovine serum (Cellgro, Manassas, VA, USA) and penicillin
(100 U/mL)/streptomycin (100 µg/mL) at 37◦C with 5% CO2.
Influenza A/PR/8/34 (H1N1) and green fluorescent protein
(GFP)-tagged H1N1 (H1N1-GFP) were donated by Dr. Jong-
Soo Lee, College of Veterinary Medicine, Chungnam National
University. Influenza A strains H3N2 (KBPV-VR-32) and H1N1
(KBPV-VR-33) were obtained from Korea Bank for Pathogenic
Viruses. H1N1, H3N2, and H1N1-GFP were propagated in the
allantoic fluid of 10-day-old chicken embryos.
Reagents and Antibodies
Recombinant mouse IFN-β, ribavirin, zanamivir, and
lipopolysaccharides from Escherichia coli were obtained
from Sigma Chemical Co. (St. Louis, MO, USA). Anti-IRF3, anti-
phospho-IRF3 anti-STAT1, anti-phospho-STAT1, anti-TBK1,
and anti-phospho-TBK1 antibodies were obtained from Cell
Signaling Technology (Boston, MA, USA), and anti-β-actin was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Antibodies against NS-1, PA, HA, PB-1, M2, and M1 were
purchased from GeneTex (San Antonio, TX, USA).
Viral Replication Inhibition Assay
A GFP-based viral replication assay was performed with a GFP-
tagged IAV as described previously (Talactac et al., 2015). RAW
264.7 cells were cultured in six-well plates (1 × 106 cells/well)
for 12 h. Cells were then exposed to a medium (RPMI, negative
control), 1000 U recombinant mouse IFN-β (positive control),
or 100 µg/mL WPS. After 12 h, cells were infected with H1N1-
GFP [multiplicity of infection (MOI) = 1]. GFP expression was
observed under a microscope after 24 h of virus infection. Cell
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TABLE 1 | Primers sequences for real-time RT-PCR.
Name Orientation Primer sequences 5′ to 3′ orientation
GAPDH Forward TGACCACAGTCCATGCCATC
Reverse GACGGACACATTGGGGGTAG
STAT1 Forward TGGTGAAATTGCAAGAGCTG
Reverse CAGACTTCCGTTGGTGGATT
IRF-7 Forward AAGCTGGAGCCATGGGTATG
Reverse GACCCAGGTCCATGAGGAAG
IFN-beta Forward TCCAAGAAAGGACGAACATTCG
Reverse TGCGGACATCTCCCACGTCAA
ISG-20 Forward AGAGATCACGGACTACAGAA
Reverse TCTGTGGACGTGTCATAGAT
viability was determined via the MTS or CCK-8 assay (pre-
treatment method). Additionally, for post-treatment analysis,
MDCK cells were seeded onto a 96-well plate and infected with
H1N1 for 2 h, after which the virus was removed and cells were
treated with WPS at 100 or 400 µg/mL for 24 h. The medium was
the negative control, and ribavirin (10 µg/mL) was the positive
control. Virus-induced cell death was measured by the MTS or
CCK-8 assay.
Viral Yield Reduction Assay
To determine the ability of WPS to inhibit virus-induced red
blood cell (RBC) hemolysis, RAW 264.7 cells were seeded in
six-well plates at 1 × 106 cells per well and were incubated
overnight to reach 70% confluence. Cells were washed with
PBS and infected with H1N1-GFP (MOI = 1). The virus yield
reduction assay was performed after 24 h of incubation with
WPS. The medium was the negative control, and IFN-β was
the positive control. Briefly, 50 µL PBS was added to each
well of a U-bottomed 96-well plate. The infected supernatant,
WPS, IFN-β, and medium were serially diluted twofold in the
previously loaded PBS. Finally, 100 µL 1% chicken RBCs were
added to each well. Assays were evaluated for 1 h of incubation
at room temperature. RBCs in negative wells sedimented and
exhibited agglutination, whereas positive wells had an opaque
appearance or displayed hemolysis with no sedimentation. Titers
are presented in HA units/50 µL (HAU/50 µL) in comparison
with the control treatment (Eisfeld et al., 2014; Abdal Dayem
et al., 2015).
Real-time RT-PCR
Total RNA was extracted using RNeasy Mini Kit (QIAGEN,
Valencia, CA, USA) according to the manufacturer’s instructions.
RNA concentrations were measured using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA), and total RNA (1 µg) was converted to cDNA using
RevoScriptTM RT PreMix (iNtRON Biotechnology, Sungnam,
Korea). Real-time RT-PCR was performed using the primers
listed in Table 1. Reactions were conducted in triplicate with a
total volume of 20 µL consisting of 0.3 µM of each primer, 10 µL
AccuPower R© 2X Greenstar qPCR Master Mix (Bioneer, Daejeon,
Korea), and 2µL template DNA. Amplification and analyses were
performed using QuantStudio 6 Flex Real-Time PCR System
(Thermo Scientific). Relative expression was calculated using
the 11Ct method. Individual transcripts in each sample were
assayed three times and normalized to GADPH mRNA levels.
Hemagglutination Assay
WPS was diluted (1–1000 µg/mL) with PBS in a round-bottomed
96-well plate. The medium was used as a negative control. H1N1,
H1N1-GFP, or H3N2 (64 HAUs in PBS) was added to each well
and incubated for 30 min at 37◦C under 5% CO2. Each sample
was mixed with 1% chicken RBCs (Innovative Research, Inc.,
Southfield, MI, USA) in PBS. After incubation for 1 h at room
temperature, plates were photographed.
NA Inhibition Assay
WPS was used at 1–2000 µg/mL. Zanamivir, a specific NA
blocker, was used as a control at 0.001–10 µg/mL. The NA
inhibition assay was performed according to the manufacturer’s
instructions using the NA-Fluor Influenza Neuraminidase Assay
kit (Life Technologies, Carlsbad, CA, USA). The reaction was
monitored using a fluorescence spectrometer in the kinetic mode
at an excitation wavelength of 365 nm and emission wavelength
of 445 nm (Abdal Dayem et al., 2015).
FIGURE 1 | Determination of the effective cytotoxic concentration of the water extract of Psoraleae semen (WPS) in (A) MDCK and (B) RAW 264.7 cells.
The indicated concentrations of WPS were added to MDCK and RAW 264.7 cells. Cell viabilities were determined by the CCK-8 or MTS assay after 24 h (n = 3
each). Data are representative of three independent experiments.
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FIGURE 2 | Anti-viral activities of pre-treatment with WPS on the influenza A/PR/8/34 (H1N1)-GFP virus in RAW 264.7 cells. (A) RAW 264.7 cells were
treated with WPS prior to influenza A virus infection. (B) Cells incubated with the medium alone, 100 µg/mL WPS, or 1000 U/mL interferon-β (recombinant mouse)
12 h prior to infection with H1N1-GFP (multiplicity of infection = 1). Images of GFP expression were obtained 24 h after virus infection (C) Cell viability was
determined 24 h after virus infection by the MTS or CCK 8 assay, and survival is presented as a percentage of the control value (cells without treatment). Data are
presented as the mean ± SD (error bars) of three independent experiments. ∗∗∗P < 0.0005 indicates a significant difference between groups. (D) Viruses were
titrated from the supernatant via the hemagglutination assay. Error bars indicate the range of values obtained from two independent experiments.
Western Blot Analysis
Total protein expression of whole cell extracts or cytoplasmic
and nuclear extracts was determined using Bradford reagent
(Bio-Rad, Hercules, CA, USA). Equal protein amounts were
resolved on sodium dodecyl sulfate gels by polyacrylamide gel
electrophoresis and transferred to PVDF membranes. After
blocking non-specific sites with 5% skim milk, membranes
were incubated with each primary (1:1000 dilution) and
secondary (1:2000 dilution) antibody, and expression was
detected using SuperSignal West Femto Chemiluminescent
Substrate (Thermo Scientific). Relative band intensity was
measured using ImageJ.
Enzyme-Linked Immunosorbent Assay
Murine IL-6, TNF-α, and IL-1β levels in culture supernatants
were determined using enzyme-linked immunosorbent assay
antibody kits (eBioscience, San Diego, CA, USA) according to the
manufacturer’s instructions.
Immunocytochemistry
RAW 264.7 cells (0.5–1.0 × 105) grown on a four-well tissue
culture slide were cultured at 37◦C for 24 h. For pre-treatment,
WPS (100 µg/mL) was added to cells, which were incubated in
a CO2 incubator at 37◦C for 12 h. After WPS treatment, the
medium was discarded, and cells were washed with PBS and
infected with H1N1 (MOI = 1) for 2 h. After infection, the
medium was discarded and cells were washed with PBS; the
medium was then added to cells, which were incubated in a CO2
incubator at 37◦C for 24 h. For post-treatment with WPS, cells
were infected with H1N1 (MOI = 1) for 2 h. After infection, the
medium was discarded, and cells were washed with PBS. Next,
WPS was added to cells, which were incubated in a CO2 incubator
at 37◦C for 24 h. At 24 h post-infection, cells were washed with
PBS three times and fixed with 4% paraformaldehyde for 30 min
and 1% Triton X-100 at room temperature. After blocking, fixed
cells were incubated with an M2-specific antibody overnight,
washed with TBS three times, and incubated with Alexa Fluor
568-goat anti-rabbit IgG antibody (1:1000; Life Technologies,
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FIGURE 3 | Stimulation of an anti-viral state by WPS in RAW 264.7 cells. Cells were treated with the medium alone (mock), 100 ng/mL lipopolysaccharides, or
100 µg/mL WPS and were then incubated at 37◦C and 5% CO2. Cells treated with the medium served as the negative controls. The supernatant from each group
was harvested at 0, 12, and 24 h and clarified by centrifugation at 3500 rpm for 20 min at 4◦C. (A) The cytokines (IL-6, TNF-α, and IFN-β) secreted in treated RAW
264.7 cells were measured by an enzyme-linked immunosorbent assay using antibody-coated enzyme-linked immunosorbent assay plates. The test was performed
in triplicate. The data show representative means ± SDs of each murine cytokine measured over time from three independent assays. Asterisks indicate a significant
difference between groups (∗∗∗P < 0.0005, ∗P < 0.05). (B,C) Immunoblot analysis was performed using the lysates of RAW 264.7 cells treated with or without WPS
to assess the expression of the phosphorylated and non-phosphorylated forms of STAT1, IRF3, TBK1, and β-actin over time. The experiment was repeated three
times independently, and similar results were obtained. ∗∗∗P < 0.0005, ∗P < 0.05 compared with the mock value.
Eugene, OR, USA) for 1 h at 25◦C. Next, cells were incubated
with DAPI for 10 min and observed by fluorescence microscopy.
High-Performance Liquid
Chromatography (HPLC) Analysis
Water extract of PS standardization was performed by HPLC
fingerprinting with chemical standards purchased from
ChemFaces (psoralen, angelicin, bavachin, and bavachinin;
Wuhan, Hubei, China). Standard solutions were prepared
by dissolving each marker component in 100% methanol at
1 mg/mL. WPS powder was accurately weighed and dissolved
in methanol at 10 mg/mL for analysis. HPLC-grade acetonitrile
was purchased from Merck (Darmstadt, Germany), and acid
was purchased from Sigma-Aldrich. Separation was performed
in a Dionex HPLC system (Dionex Co., Sunnyvale, CA, USA)
equipped with an ultimate 3000 series A binary pump, an auto-
sampler, a column oven, and a diode array UV/VIS detector.
Data analysis was performed using Dionex Chromeleon. All
chromatographic separations were performed on Acclaim
C18 (4.6 × 250 mm2, 5 µm, Dionex) at 30◦C. HPLC analysis
was performed in accordance with the methods reported by
Zhao et al. (2005) with some modifications. Briefly, the mobile
phase consisted of water containing (A) 0.1% acetic acid and (B)
acetonitrile with gradient elution at a flow rate of 1 mL/min.
Gradient elution was performed as follows: 40–50% (v/v) B at
0–15 min, 50–60% B at 15–35 min, 60–70% B at 35–45 min,
70–80% B at 45–55 min, and 80% B at 55–60 min. The injection
volume was 10 µL, and detection wavelength was 245 nm.
Statistics
All data are presented as mean ± SD of at least three
independent experiments. Statistical significance of mean
values in the two groups or treatment effects were evaluated
via one-way ANOVA with Dunnett’s test. Analyses were
performed using GraphPad PRISM software R© (GraphPad PRISM
software Inc., Version 5.02, La Jolla, CA, USA). Values of
∗P < 0.05, ∗∗P < 0.005, and ∗∗∗P < 0.0005 indicated statistical
significance.
RESULTS
Effects of WPS on Cell Viability
WPS cytotoxicities in RAW 264.7 and MDCK cells were
evaluated using the CCK-8 assay after 24 h treatment to
determine the optimal concentration that would provide anti-
viral activity with minimum toxicity. The results illustrated that
WPS concentrations of≤400 µg/mL had no significant effects on
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FIGURE 4 | Induction of interferon (IFN)-related gene and IFN-stimulating gene (ISG) transcripts by WPS in RAW 264.7 cells. Cells were treated with the
medium alone (mock), 100 ng/mL lipopolysaccharides, or 100 µg/mL WPS and were then incubated at 37◦C with 5% CO2. The time-dependent changes in mRNA
expression (A,B; STAT1, IFN-β, IRF-7, and ISG-20) were examined after treatment in RAW 264.7 cells. ∗∗∗P < 0.0005, ∗∗P < 0.005, and ∗P < 0.05 compared with
the mock value.
cell viability, indicating that WPS was not toxic to RAW 264.7 and
MDCK cells (Figures 1A,B). Therefore, subsequent experiments
were performed using concentrations of ≤100 µg/mL.
WPS Increased RAW 264.7 Cell Survival
To evaluate anti-influenza virus activity of WPS, viral replication
using GFP-expressing viruses was examined in cells pre-treated
with WPS (Figure 2A). H1N1-GFP-infected RAW 264.7
cells with pre-treated WPS exhibited markedly reduced GFP
expression compared to that in the untreated group (Figure 2B).
Figure 2C shows that cell death significantly decreased in WPS-
treated cells compared with that in the virus-only group within
24 h of H1N1-GFP infection. We found that viral supernatant
titers of H1N1-GFP-, IFN-beta/H1N1-GFP-, and WPS/H1N1-
GFP-infected cells were significantly reduced by WPS or IFN-β
treatment (0 HAUs) compared to that in the virus-only group
(64 HAUs; Figure 2D). These results illustrate that WPS pre-
treatment reduced H1N1-GFP replication in RAW 264.7 cells.
WPS Induced IFN-β and
Pro-inflammatory Cytokine Secretion
and Type I IFN Signaling Pathway
Activation in RAW 264.7 Cells
The anti-viral response of WPS may be related to the innate
immune response through the expression of cytokines, such as
IL-6 and IFN-β. To correlate these observations with the IFN-
inducing signaling pathway, we examined the phosphorylation
of interferon-related signaling molecules. For elucidating the
possible mechanism by which WPS inhibited viral replication, we
first measured secreted cytokine levels (IFN-β, IL-6, and TNF-α)
in treated and untreated virus-infected RAW 264.7 cells. As
shown in Figure 3A, WPS induced high levels of IL-6, TNF-α,
and IFN-β secretion (Figure 3A) after 24 h compared to levels
in medium- or lipopolysaccharide-treated positive controls. The
results indicate that IL-6, TNF-α, and IFN-β can be induced
by WPS, thus mediating the anti-viral state in RAW 264.7
cells. In addition, the anti-viral effect of WPS may be related
to the innate immune response through cytokine expression,
such as IFN-β and IL-6. To correlate the aforementioned
observations with the IFN signaling pathway, we examined the
effects of WPS on type I IFN-related protein phosphorylation.
For this purpose, whole cell lysates of WPS-treated RAW
264.7 cells were subjected to immunoblotting to analyze the
expression of the phosphorylated and non-phosphorylated forms
of STAT1, IRF3, and TBK1. As shown in Figure 3B, WPS
treatment in RAW 264.7 cells upregulated phosphorylation
of STAT1, IRF-3, and TBK1, which are important molecules
in the type I IFN signaling pathway (Trinchieri, 2010). IRF3
phosphorylation indicates IRF3 molecule translocation into the
nucleus and transcription initiation of type I IFNs. Consequently,
the produced type I IFNs bind to proteins in JAK-STAT
pathway (Horvath, 2004; Trinchieri, 2010), leading to the
phosphorylation of STAT1 and transcriptional activation of
interferon-stimulating genes (ISGs). Our results indicate that
WPS treatment induces IRF3, STAT1, and TBK1 phosphorylation
at 12 h to levels compared to findings in untreated cells
(Figures 3B and 2C).
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FIGURE 5 | WPS inhibited influenza A/PR/8/34 (H1N1) infection in MDCK cells. (A) MDCK cells were treated with WPS before or after viral adsorption.
(B) Cells were incubated with the medium alone (mock), 100 µg/mL WPS, or 10 µg/mL ribavirin before or after infection with H1N1-GFP (multiplicity of
infection = 1). Cell viability was determined 24 h after viral infection by the MTS or CCK 8 assay, and survival is presented as a percentage of the control value
(untreated cells). Data are presented as the mean ± SD (error bars) of three independent experiments.
We further confirmed the interaction between WPS and
IFN-stimulated gene induction in RAW 264.7 cells. A time-
dependent increase in the mRNA expression of STAT1, IRF-7,
IFN-β, and ISG-20 was observed in WPS-treated RAW 264.7
cells compared with levels in untreated cells (Figure 4A). In
addition, upregulation of IFN-β and ISG was noted at 24 h. The
observed pattern was similar to that of lipopolysaccharide-treated
positive control (Figure 4A), and transcription of IRF-7 and ISG-
20 increased by 16- and 150-fold, respectively. The overall results
suggest that WPS induces the anti-viral state by modulating
the IFN signaling pathway and IRF-7 and ISG-20 expression in
RAW264.7 cells, which may result in viral replication inhibition
(Espert et al., 2005; Lazear et al., 2013; Sheikh et al., 2014).
WPS Inhibited H1N1 Infection in MDCK
Cells
To investigate whether WPS inhibited IAV infection in MDCK
cells, we examined viral replication in MDCK cells treated with
WPS before and after infection with H1N1 (Figure 5A). WPS-
pre-treated and WPS-post-treated (100 and 400 µg/mL) cells
displayed significantly decreased cell death compared to that in
cells exposed only to H1N1 (Figure 5B), indicating that both pre-
and post-treatment with WPS reduces viral replication in MDCK
cells.
WPS Reduced H1N1 Viral Protein
Expression
To evaluate whether WPS inhibited H1N1 viral protein
expression, we performed Western blotting in RAW 264.7 cells
treated with WPS before and after H1N1 infection. Relative
protein expression levels of viral proteins (PA, HA, PB-1,
M2, M1) as analyzed by Western blotting were significantly
lower in RAW 264.7 cells with pre- or post-treatment of WPS
than in those treated with the medium alone (Figures 6A,B).
WPS pre-treatment decreased M1, M2, and PB1 levels by
0.8-, 0.9-, and 0.9-fold, respectively. Post-treatment with WPS
decreased M1, HA, and PB1 levels by 0.9-, 0.4-, and 0.9-
fold, respectively (Figures 6C,D). Further, we demonstrated, by
immunofluorescent analysis, that M2 protein levels significantly
decreased in RAW 264.7 cells treated with WPS before and
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FIGURE 6 | WPS inhibited influenza A/PR/8/34 (H1N1) protein expression in RAW 264.7 cells. RAW 264.7 cells were treated with WPS (100 µg/mL),
interferon (IFN)-β (1000 U/mL, recombinant mouse, pre-treatment positive control), ribavirin (10 µg/mL, post-treatment positive control), or the medium only
(negative control) before (A,C) or after (B,D) after viral adsorption. Influenza A virus protein levels (NS-1, PA, HA, PB-1, M1, M2) in cell lysates were analyzed by
Western blotting, and β-actin expression was analyzed as an internal control. Data are presented as the mean ± SD (error bars) and are representative of three
independent experiments. ∗∗∗P < 0.0005, ∗∗P < 0.005, ∗P < 0.05 compared with the mock value. RAW 264.7 cells were infected with H1N1 (multiplicity of
infection = 1) before (E) or after WPS treatment (F). Cells were observed by fluorescence microscopy using an M2-specific antibody. The cells were also stained with
DAPI. The merged image illustrates the cytoplasmic localization of viral M2 (red) and selected nuclei (DAPI, blue).
after H1N1 exposure compared with levels in untreated cells
(Figures 6E,F). Therefore, these data revealed that pre- and post-
treatment with WPS reduced H1N1 virus protein expression.
Inhibitory Effects of WPS on NA Activity
NA is a key viral protein responsible for releasing newly
produced virus particles and the recognition and cleavage of
target cell receptor sialic acid moieties (N-acetylneuraminic acid)
on infected cells (Chazal and Gerlier, 2003). Additionally, NA
activity is required for preventing the self-aggregation of virus
particles via the cleavage of sialic acids bound to the virus
surface. We therefore tested the potential effect of WPS on
viral NA activity. NA activity from H1N1-GFP and H1N1-WT
decreased significantly with WPS and zanamivir used as the
positive control (Figure 7A). Moreover, WPS (1000 µg/mL)
treatment had a significantly suppressive effect on NA activity
for H3N2 (37.5%) and H1N1-WT (30%). The results suggest that
WPS has additional inhibitory effects on the IAV release step
through inhibiting NA, particularly at high concentrations.
Inhibitory Effects of WPS on Virus
Adsorption
IAVs can induce hemagglutination in RBCs. Therefore, we
investigated whether WPS alters viral adsorption onto RBCs,
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FIGURE 7 | Measurement of the anti-viral activity of WPS using neuraminidase inhibition and hemagglutination inhibition assays. (A) Influenza A viruses
(H1N1 and H3N2) were added at 32 hemagglutination units (HAUs) to the indicated concentrations of WPS, zanamivir (positive control), or PBS (negative control);
were mixed with NA-FluorTM substrate; and were incubated at 37◦C for 1 h away from light. Fluorescence was monitored (excitation, 365 nm; emission, 445 nm).
Data are representative of two independent experiments, and results were reproducible. (B) Hemagglutination inhibition assay: WPS was serially diluted using PBS
and added to equal volumes of the viruses (64 HAUs). To assess red blood cell (RBC) hemolysis inhibition, 50 µL 1% chicken RBCs were added to each well of a
96-well plate and incubated for 1 h at room temperature. Data are representative of two independent experiments, and results were reproducible.
resulting in hemagglutination. WPS decreased H3N2 viral titers
by twofold in the HA assay (Figure 7B). However, WPS treatment
did not inhibit RBC hemolysis in H1N1-infected cells (data not
shown). These results suggest that the potent hemagglutination-
inhibiting activity of WPS is attributed to a direct interaction with
H3N2, particularly at high concentrations.
HPLC Analysis of WPS
The UV wavelength of chromatograms was adjusted on the
basis of the maximum UV absorption wavelengths of the
following major standard compounds: psoralen, 246 nm;
angelicin, 248 nm; bavachin, 237 nm; and bavachinin,
237 nm; therefore, the analysis was performed at 245 nm.
WPS constituents were determined by HPLC-diode array
detection analysis, and each peak of the UV spectra was
compared with that of representative standard compounds.
As shown in Figure 8, HPLC-diode array detection analysis
revealed a single peak specific for chemicals contained in
WPS extracts at the following retention times: psoralen,
10.03 min; angelicin, 10.74 min; bavachin, 19.36 min; and
bavachinin, 35.52 min. The following values were observed
for the standard compounds: psoralen, 10.02 min; angelicin,
10.73 min; bavachin, 19.36 min; and bavachinin, 35.52 min
(Figure 8).
DISCUSSION
Herbal medicines have gained popularity to control viral and
bacterial infections; they have a low incidence of side effects
(Martin and Ernst, 2003; Ehrhardt et al., 2007; Ge et al.,
2010). Herbal extracts have anti-influenza effects (He et al.,
2011; Haruyama and Nagata, 2013; Makau et al., 2013). In
the present study, we demonstrated that WPS protects against
infection by IAV subtypes in MDCK and RAW 264.7 cells.
Psoralen and bakuchiol are the dominant compounds in WPS,
and they have anti-viral activity against many viruses such as
influenza and herpes simplex viruses (Nakashima et al., 1979;
Redfield et al., 1981). Recently, bakuchiol was found to exert
anti-influenza viral activity via Nrf2 activation (Shoji et al.,
2015). However, no detailed mechanism has been described for
the immunoregulatory and immune enhancing effects of WPS.
Nevertheless, we were unable to define the mechanism of the
anti-viral effects of WPS. WPS sufficiently protected against
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FIGURE 8 | Measurement of the representative component in WPS by high-performance liquid chromatography. Psoralen (1), angelicin (2), bavachin (3),
and bavachinin (4) were identified in the standard mixture (A) and WPS (B) at a wavelength of 245 nm. Data are representative of three independent experiments,
and results were reproducible (Supplementary Figure 1).
viral replication by modulating the innate immune response
and inducing an anti-viral state. Moreover, we found that WPS
enhanced the survival of IAV-infected MDCK and RAW 264.7
cells and inhibited influenza A viral infection and growth as well
as viral protein expression (Figures 2 and 6). Innate immune
cells, such as macrophages, initially recognize viral infections
and rapidly induce the production of type I IFNs and pro-
inflammatory cytokines, thereby generating anti-viral immune
responses. We hypothesize that WPS induces an anti-viral state
in murine macrophage cells by inducing anti-viral cytokines,
modulating immune response, and inhibiting viral replication.
Thus, we determined that type I IFN and IFN-stimulated gene
levels (Figures 3 and 4) were altered in WPS-pre-treated RAW
264.7 cells. The effects of WPS on the phosphorylation of type
I IFN signaling proteins, such as IRF3, TBK1, and STAT1,
were examined in extract-treated RAW 264.7 cells. Type I IFNs
upregulate the anti-viral status of infected cells (Sharma et al.,
2003; Chiu et al., 2009). In our study, we found that WPS pre-
treatment induced IRF3, TBK1, and STAT1 phosphorylation,
thereby providing evidence of the downstream activation of
signaling molecules in the type I IFN pathway.
This is the first study reporting that WPS possesses anti-
influenza activity. We found that WPS chirality is important for
this activity; thus, WPS should be considered a novel anti-H1N1
or -H3N2 drug. Our pre-incubation experiment illustrated that
WPS more strongly inhibited H3N2 strains than H1N1 strains in
HA and NA inhibition assays (Figure 7). This may reflect strain-
associated differences in HA and NA viral proteins between the
H3N2 and H1N1 strains, or the host cell response.
CONCLUSION
We found that WPS can be a significant alternative anti-viral
therapeutic agent for disrupting viral infection through the
activation of type I IFN-mediated signaling, thereby inducing
an anti-viral state in RAW 264.7 cells. Moreover, the anti-
influenza effects of WPS are mediated by direct HA and NA
inhibition. However, this study demonstrated that WPS had
anti-viral activity only under in vitro conditions. Therefore,
extensive future investigations for evaluating the potential of
WPS for in vivo anti-viral therapeutic applications are warranted.
An important step in this direction will be the identification
of individual anti-viral agents from WPS and the analysis of
their pharmacokinetic properties. In addition, specific signaling
pathways and adequate dosage and efficacy duration of the extract
in the host should be examined. The study results suggest that
WPS has anti-viral activity against the influenza A subtypes
H1N1 and H3N2. Our findings describe a possible mechanism
of action of the anti-viral effects of WPS involving type I IFN
signaling pathway activation and direct HA and NA inhibition.
Thus, our results indicate that WPS has the potential to be an
effective herbal remedy for the prophylaxis and treatment of
influenza virus infection.
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